REG - Oxford Biomedica PLC - Grant of options
RNS Number : 2108BOxford Biomedica PLC08 June 2021Grant of options
London, UK - 08 June 2021: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group announces that on 08 June 2021 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2021 LTIP Awards
Name of individual
Title
Number of shares subject to the 2021 DBP award
Number of shares subject to the 2021 LTIP award
Total shares over which options now held
Percentage of current issued share capital under option
John Dawson
Chief Executive Officer
20,221
80,460
848,393
1.0%
Stuart Paynter
Chief Financial Officer
11,642
47,966
247,902
0.3%
James Miskin
Chief Technical Officer
4,897
18,943
154,914
0.2%
Kyriacos Mitrophanous
Chief Scientific Officer
4,944
19,125
171,545
0.2%
Nick Page
Chief Operations Officer
5,170
19,999
89,436
0.1%
Helen Stephenson-Ellis
Chief People Officer
3,331
13,131
75,758
0.09%
Jason Slingsby
Chief Business Officer
4,595
18,114
108,867
0.1%
Natalie Walter
General Counsel
4,143
16,028
66,905
0.08%
Under the terms of the DBP, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.
The LTIP awards are subject to performance conditions. As set out in the 2020 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2021, 2022 and 2023) and strategic milestones (20% of the award). Details of the measures are included in the 2020 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.
The LTIP awards granted to John Dawson and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The2021 awards granted to other participants will vest and be released following the assessment of the performance condition.
The above table reflects the grant of an award (1,320) to rectify an administrative error in the 2020 LTIP award granted to the General Counsel and the lapse of an award (7,875) to rectify an administrative error in the 2020 LTIP award granted to the Chief Financial Officer ("CFO") on 26 June 2020. These amendments were also reflected in the Company's 2020 Report & Accounts.
RSU awards
In addition, on 08 June 2021 a nil-cost share option over 4,406 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff. The RSU award is not subject to performance conditions and will become exercisable from the third anniversary of the grant date. The total shares over which options are held by Alexander Lewis is 69,227, representing 0.08% of the current issued share capital under option.
The current issued share capital of the Company is 82,555,443 ordinary shares of 50 pence each.
Notification of Dealing Form
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
John Dawson
2.
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
80,460
2021 DBP Award
Price
Volume
Nil
20,221
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 100,681 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Stuart Paynter
2.
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
47,966
2021 DBP Award
Price
Volume
Nil
11,642
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 59,608 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
James Miskin
2.
Reason for the notification
a)
Position/status
Chief Technical Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
18,943
2021 DBP Award
Price
Volume
Nil
4,897
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 23,840 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Kyriacos Mitrophanous
2.
Reason for the notification
a)
Position/status
Chief Scientific Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
19,125
2021 DBP Award
Price
Volume
Nil
4,944
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 24,069 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Nick Page
2.
Reason for the notification
a)
Position/status
Chief Operations Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
19,999
2021 DBP Award
Price
Volume
Nil
5,170
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 25,169 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Helen Stephenson-Ellis
2.
Reason for the notification
a)
Position/status
Chief People Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2020 LTIP Award
Price
Volume
Nil
13,131
2021 DBP Award
Price
Volume
Nil
3,331
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 16,462 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Jason Slingsby
2.
Reason for the notification
a)
Position/status
Chief Business Officer
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 LTIP Award
Price
Volume
Nil
18,114
2021 DBP Award
Price
Volume
Nil
4,595
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 22,709 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Natalie Walter
2.
Reason for the notification
a)
Position/status
General Counsel
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2020 LTIP Award
Price
Volume
Nil
16,028
2021 DBP Award
Price
Volume
Nil
4,143
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 20,171 shares in total
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
1.
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)
Name
Alexander Lewis
2.
Reason for the notification
a)
Position/status
Chief of Staff
b)
Initial notification/
amendment
Initial Notification
3.
Details of the Issuer
a)
Name
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
b)
Nature of the transaction
Grant of award over Ordinary Shares under the Company's Executive Share Option Scheme. No consideration was paid for the grant of awards.
c)
Price(s) and volumes(s)
2021 RSU Award
Price
Volume
Nil
4,406
d)
Aggregated information
- Aggregate volume
- Price
4,406
N/A
e)
Date of the transaction
2021-06-08
f)
Place of the transaction
Outside of trading venue
-Ends-
For further information, please contact:
Oxford Biomedica plc:
Natalie Walter, Company Secretary
Tel: +44 (0)1865 783 000
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFZGGVFRMGMZM
Recent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Update on CDMO Services
AnnouncementREG - Oxford Biomedica PLC - Board Changes
AnnouncementREG - Oxford Biomedica PLC - Updated Financial Guidance and 2023 Trading
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Appointment of Joint Corporate Broker
Announcement